RNA-focused digital therapeutics company Flamingo Therapeutics added a new member to its board of directors, Dr. Ezra Cohen.
Flamingo produces RNA therapies for oncology and is backed by investors such as Andera Partners, Bpifrance Large Venture, Perceptive Advisors, Sphera and VIB.
Dr. Cohen has a history in the development of pharmaceuticals, especially head and neck cancers.
"The science...
